Nanobiosym® (NBS) is an innovation engine dedicated to creating a new science that emerges from the holistic integration of physics, biomedicine, and nanotechnology. NBS focuses on incubating transformational technologies that have the potential for game-changing impact and commercializing and scaling up these technologies for deployment in developed and developing world markets. NBS leverages science and technology to address our planet’s greatest unmet needs in global health, energy and the environment. Nanobiosym® Diagnostics (NBSDx) focuses on the commercialization of its proprietary technology platform, that can rapidly and accurately detect genetic fingerprints from any biological organism, empowering people worldwide with rapid, affordable, and portable diagnostic information about their own health. To maximize global humanitarian impact, we have spearheaded the Nanobiosym Global Initiative, which is building innovative public-private partnerships with governments, NGO’s, academic, industrial and global thought leaders to help bring emerging technologies to address some of the world’s most pressing challenges.
Looking for a particular Nanobiosym employee's phone or email?
The Nanobiosym annual revenue was $6 million in 2026.
Anita Goel is the President of Nanobiosym.
5 people are employed at Nanobiosym.
Nanobiosym is based in Cambridge, Massachusetts.
The NAICS codes for Nanobiosym are [541, 54, 5417].
The SIC codes for Nanobiosym are [87, 873].